Aethlon Medical (NASDAQ:AEMD) Shares Pass Below 200-Day Moving Average – Should You Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.35 and traded as low as $1.35. Aethlon Medical shares last traded at $1.36, with a volume of 140,847 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aethlon Medical presently has an average rating of “Reduce”.

Aethlon Medical Stock Down 27.0%

The firm has a 50 day moving average of $2.14 and a 200 day moving average of $2.33. The firm has a market cap of $2.11 million, a PE ratio of -0.06 and a beta of 1.49.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.